Shots:

• The approval is based on four trials assessing Lokelma vs PBO in patients with hyperkalemia treated for up to 12 months
• The study resulted in a median time of 2.2 hours in achieving normal potassium levels in the blood- 98% achieved normal levels in 48 hours- rapid reduction of potassium in blood as early as one hour with one dose and a sustained treatment effect for up to one year- well-tolerated data
• Lokelma is an insoluble oral powder formulation that results as a highly selective potassium-removing medicine approved in the US- EU- Canada to treat hyperkalemia and is under review in Japan with expected results in H1’20

Click here to read full press release/ article 

Ref: AstraZeneca | Image: AstraZeneca